Literature DB >> 10037741

Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain.

D Moechars1, I Dewachter, K Lorent, D Reversé, V Baekelandt, A Naidu, I Tesseur, K Spittaels, C V Haute, F Checler, E Godaux, B Cordell, F Van Leuven.   

Abstract

Transgenic mice overexpressing different forms of amyloid precursor protein (APP), i.e. wild type or clinical mutants, displayed an essentially comparable early phenotype in terms of behavior, differential glutamatergic responses, deficits in maintenance of long term potentiation, and premature death. The cognitive impairment, demonstrated in F1 hybrids of the different APP transgenic lines, was significantly different from nontransgenic littermates as early as 3 months of age. Biochemical analysis of secreted and membrane-bound APP, C-terminal "stubs," and Abeta(40) and Abeta(42) peptides in brain indicated that no single intermediate can be responsible for the complex of phenotypic dysfunctions. As expected, the Abeta(42) levels were most prominent in APP/London transgenic mice and correlated directly with the formation of amyloid plaques in older mice of this line. Plaques were associated with immunoreactivity for hyperphosphorylated tau, eventually signaling some form of tau pathology. In conclusion, the different APP transgenic mouse lines studied display cognitive deficits and phenotypic traits early in life that dissociated in time from the formation of amyloid plaques and will be good models for both early and late neuropathological and clinical aspects of Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10037741     DOI: 10.1074/jbc.274.10.6483

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  214 in total

1.  Intraneuronal Abeta42 accumulation in human brain.

Authors:  G K Gouras; J Tsai; J Naslund; B Vincent; M Edgar; F Checler; J P Greenfield; V Haroutunian; J D Buxbaum; H Xu; P Greengard; N R Relkin
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

Review 2.  Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease.

Authors:  P T Lansbury
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

3.  A novel beta-sheet breaker, RS-0406, reverses amyloid beta-induced cytotoxicity and impairment of long-term potentiation in vitro.

Authors:  Yasuhiro Nakagami; Satoko Nishimura; Takako Murasugi; Isao Kaneko; Masaki Meguro; Shinji Marumoto; Hiroshi Kogen; Kazuo Koyama; Tomiichiro Oda
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

4.  Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the london mutant of human APP in neurons.

Authors:  J Van Dorpe; L Smeijers; I Dewachter; D Nuyens; K Spittaels; C Van Den Haute; M Mercken; D Moechars; I Laenen; C Kuiperi; K Bruynseels; I Tesseur; R Loos; H Vanderstichele; F Checler; R Sciot; F Van Leuven
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

5.  Preparation and characterization of toxic Abeta aggregates for structural and functional studies in Alzheimer's disease research.

Authors:  Asad Jan; Dean M Hartley; Hilal A Lashuel
Journal:  Nat Protoc       Date:  2010-06-03       Impact factor: 13.491

Review 6.  Synaptic plasticity in animal models of early Alzheimer's disease.

Authors:  Michael J Rowan; Igor Klyubin; William K Cullen; Roger Anwyl
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2003-04-29       Impact factor: 6.237

Review 7.  Vaccines for Alzheimer's disease: how close are we?

Authors:  Christopher Janus
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

8.  Amyloid beta(1-42) peptide alters the gating of human and mouse alpha-bungarotoxin-sensitive nicotinic receptors.

Authors:  Francesca Grassi; Eleonora Palma; Raffaella Tonini; Mascia Amici; Marc Ballivet; Fabrizio Eusebi
Journal:  J Physiol       Date:  2003-01-17       Impact factor: 5.182

9.  Beta-amyloid prevents excitotoxicity via recruitment of glial glutamate transporters.

Authors:  Atsushi Baba; Kazuhiko Mitsumori; Maki K Yamada; Nobuyoshi Nishiyama; Norio Matsuki; Yuji Ikegaya
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-09-04       Impact factor: 3.000

10.  The familial Alzheimer's disease APPV717I mutation alters APP processing and Tau expression in iPSC-derived neurons.

Authors:  Christina R Muratore; Heather C Rice; Priya Srikanth; Dana G Callahan; Taehwan Shin; Lawrence N P Benjamin; Dominic M Walsh; Dennis J Selkoe; Tracy L Young-Pearse
Journal:  Hum Mol Genet       Date:  2014-02-12       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.